-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AEGQUmSNSwjHXC9uDXXyiFUdPQ9zeGKm6G0bv8xmLuC4ICuNM0UKejZR4aPhZQJi bWoqCmkyN3EtaHERkV1pbg== 0000947871-99-000552.txt : 19991203 0000947871-99-000552.hdr.sgml : 19991203 ACCESSION NUMBER: 0000947871-99-000552 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19991202 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ANDRX CORP CENTRAL INDEX KEY: 0000911755 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 650366879 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-50129 FILM NUMBER: 99767893 BUSINESS ADDRESS: STREET 1: 4001 SW 47 AVE STE 201 CITY: FORT LAUDERDALE STATE: FL ZIP: 33314 BUSINESS PHONE: 3055840300 MAIL ADDRESS: STREET 1: 4001 SOUTHWEST 47TH AVE STREET 2: STE 201 CITY: FT LAUDERDALE STATE: FL ZIP: 33314 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: WATSON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884629 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 953872914 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 311 BONNIE CIRCLE CITY: CORONA STATE: CA ZIP: 91720 BUSINESS PHONE: 9092701400 MAIL ADDRESS: STREET 1: 311 BONNIE CIRCLE CITY: CORONA STATE: CA ZIP: 91720 SC 13G 1 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. __)* Andrx Corporation -------------------------------------- (Name of Issuer) Common Stock, Par Value $.001 per share -------------------------------------- (Title of Class of Securities) 03455110 -------------------------------------- (CUSIP Number) Not Applicable -------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |X| Rule 13d-1(c) |_| Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this page shall not be deemed to be "filed" for the purpose of Section18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Cusip 03455110 Page 2 of 4 Pages 13G - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSONS S.S. OR IRS IDENTIFICATION NO. OF ABOVE PERSON Watson Pharmaceuticals, Inc. ("Watson") 95-3872914 - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) ___ Not Applicable (b) ___ - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION a Nevada corporation - -------------------------------------------------------------------------------- NUMBER OF 5 SOLE VOTING POWER SHARES 4,977,738 ----------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER OWNED BY -0- ----------------------------------------------------- EACH 7 SOLE DISPOSITVE POWER REPORTING 4,977,738 ----------------------------------------------------- PERSON 8 SHARED DISPOSITIVE POWER WITH -0- - -------------------------------------------------------------------------------- 9 AGGREGATE AMMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 4,977,738 - -------------------------------------------------------------------------------- 10 CHECK THE BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES * Not Applicable - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 15.8% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILING Cusip 03455110 Page 3 of 4 Pages Schedule 13 G (Cont.) Item 1(a)- Name of Issuer: Andrx Corporation Item 1(b)- Address of Issuer's Principal Executive Offices: 4001 SW 47th Avenue Suite 201 Fort Lauderdale, FL 33314 Item 2(a)- Name of Person Filing: Watson Pharmaceuticals, Inc. Item 2(b)- Address of Principal Business Office: 311 Bonnie Circle Corona, CA 92880 Item 2(c)- Citizenship: Nevada, USA (Place of Incorporation) Item 2(d)- Title of Class of Securities: Common Stock Item 2(e)- Cusip Number: 03455110 Item 3- This statement is being filed pursuant to Rule 13d-1(c). Item 4(a)- Amount beneficially owned: 4,977,738 Item 4(b)- Percent of Class: 15.8% Item 4(c)- _____ Number of Shares to which Watson has: (i)--sole power to vote or to direct the vote: 4,977,738 (ii)-shared power to vote or to direct the vote: -0- (iii)sole power to dispose or to direct the disposition of: 4,977,738 (iv)-shared power to dispose or to direct the disposition of: -0- Item 5 - Ownership of Five Percent or Less of a Class: Not Applicable Item 6 - Ownership of More than Five percent on Behalf of Another Person: Not applicable Cusip 03455110 Page 4 of 4 Pages Schedule G (Cont.) Item 7- Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: Not Applicable Item 8- Identification and Classification of Members of the Group: Not Applicable Item 9- Notice of Dissolution of Group: Not Applicable Item 10- Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: December 2, 1999 WATSON PHARMACEUTICALS, INC. / S / Robert C. Funsten --------------------------------- By: Robert C. Funsten Senior Vice President, General Counsel and Secretary -----END PRIVACY-ENHANCED MESSAGE-----